



(11)

EP 3 138 925 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C12Q 1/6832 ^(2018.01) **C12Q 1/6841** ^(2018.01)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(45) Date of publication and mention
of the grant of the patent:
13.05.2020 Bulletin 2020/20

(21) Application number: **16180119.6**

(22) Date of filing: **27.05.2009**

(54) **COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR ERKENNUNG VON CHROMOSOMALEN ABWEICHUNGEN MIT NEUEN HYBRIDISIERUNGSPUFFERN

COMPOSITIONS ET PROCÉDÉS POUR LA DÉTECTION D'ABERRATIONS CHROMOSOMIQUES AVEC DE NOUVEAUX TAMPONS D'HYBRIDATION

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK TR**

(30) Priority: **27.05.2008 US 56089 P**
27.05.2008 DK 200800727
26.02.2009 US 155683 P
27.02.2009 DK 200900278

(43) Date of publication of application:
08.03.2017 Bulletin 2017/10

(60) Divisional application:
20167307.6

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
13164094.8 / 2 636 756
09757890.0 / 2 285 982

(73) Proprietor: **Agilent Technologies, Inc.**
Santa Clara, CA 95051 (US)

(72) Inventors:
• **MATTHIESEN, Steen Hauge**
3400 Hillerød (DK)
• **PETERSEN, Kenneth H.**
2765 Smørum (DK)
• **POULSEN, Tim Svenstrup**
2970 Hørsholm (DK)

(74) Representative: **Grünecker Patent- und
Rechtsanwälte**
PartG mbB
Leopoldstraße 4
80802 München (DE)

(56) References cited:
WO-A1-00/69899 WO-A1-92/07956
US-A- 4 886 741 US-A- 5 521 061

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 138 925 B8

- OLSEN K.E. ET AL.,: "amplification of HER2 and TOP2A and deletion of TOP2a genes in breast cancer investigated by new FISH probes", ACTA ONCOLOGICA, vol. 43, no. 1, 2004, pages 34-42, XP009127838,
- Anonymous: "TOP2A FISH pharmDx kit Code K5333", DAKO PRODUCT INFORMATION , 24 May 2007 (2007-05-24), pages 1-33, XP002562618, Retrieved from the Internet:
URL:http://www.dakogmbh.de/prod_downloadpackageinsert.pdf?objectid=114968002 [retrieved on 2010-01-12]